- Home
- ARHS vs DNLI Comparison
ARHS vs DNLI Comparison
Compare ARHS & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARHS
- DNLI
- Stock Information
- Founded
- ARHS 1986
- DNLI 2013
- Country
- ARHS United States
- DNLI United States
- Employees
- ARHS N/A
- DNLI N/A
- Industry
- ARHS Other Specialty Stores
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ARHS Consumer Discretionary
- DNLI Health Care
- Exchange
- ARHS Nasdaq
- DNLI Nasdaq
- Market Cap
- ARHS 1.7B
- DNLI 1.8B
- IPO Year
- ARHS 2021
- DNLI 2017
- Fundamental
- Price
- ARHS $7.95
- DNLI $12.74
- Analyst Decision
- ARHS Buy
- DNLI Strong Buy
- Analyst Count
- ARHS 12
- DNLI 16
- Target Price
- ARHS $12.38
- DNLI $37.57
- AVG Volume (30 Days)
- ARHS 2.1M
- DNLI 1.7M
- Earning Date
- ARHS 05-08-2025
- DNLI 05-06-2025
- Dividend Yield
- ARHS N/A
- DNLI N/A
- EPS Growth
- ARHS N/A
- DNLI N/A
- EPS
- ARHS 0.49
- DNLI N/A
- Revenue
- ARHS $1,271,107,000.00
- DNLI N/A
- Revenue This Year
- ARHS $10.22
- DNLI N/A
- Revenue Next Year
- ARHS $8.28
- DNLI $372.05
- P/E Ratio
- ARHS $16.24
- DNLI N/A
- Revenue Growth
- ARHS N/A
- DNLI N/A
- 52 Week Low
- ARHS $6.61
- DNLI $10.57
- 52 Week High
- ARHS $19.81
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- ARHS 43.71
- DNLI 42.15
- Support Level
- ARHS $7.22
- DNLI $12.37
- Resistance Level
- ARHS $8.23
- DNLI $13.63
- Average True Range (ATR)
- ARHS 0.76
- DNLI 1.24
- MACD
- ARHS 0.03
- DNLI 0.23
- Stochastic Oscillator
- ARHS 53.39
- DNLI 50.94
About ARHS Arhaus Inc.
Arhaus Inc is a growing lifestyle brand and omnichannel retailer of premium home furniture. The company offers merchandise in a number of categories, including furniture, outdoor, lighting, textiles, and decor through its Retail and eCommerce sales channels.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.